Pfizer (PFE) option implied volatility flat amid the spread of coronavirus into CDC update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE) Following 4Q
January 29, 2020 7:04 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $53.00 price target on Pfizer (NYSE: PFE) following the company's 4Q earnings report. PFE reported 4Q19 adjusted diluted EPS of $0.55, $0.03 lower than consensus.
PFE presented its 2020 sales and EPS guidance of $48.5-50.5B and... More
Pfizer (PFE) Trades at Session High, Up 1.2%
January 27, 2020 2:30 PM ESTPfizer (NYSE: PFE) Trades at Session High, Up 1.2%
... More